Bayer HealthCare’s Xarelto approved in Korea
The Korea Food and Drug Administration granted on April 13 Bayer HealthCare marketing authorization for the anticoagulant Xarelto (rivaroxaban), taken as one tablet, once-daily, for the prevention of venous thromboembolic events (VTE) in patients wh...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
